123 related articles for article (PubMed ID: 36926936)
1. Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time.
Mouhtar El Hálabi S; Valdés Delgado T; Maldonado Pérez B; Belvis Jiménez M; Argüelles Arias F
Rev Esp Enferm Dig; 2023 Nov; 115(11):657. PubMed ID: 36926936
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Multiple Cerebral Infarction Associated with Cerebral Vasculitis in a Patient with Ulcerative Colitis.
Yasuda T; Takagi T; Hasegawa D; Hirose R; Inoue K; Dohi O; Yoshida N; Kamada K; Uchiyama K; Ishikawa T; Konishi H; Naito Y; Itoh Y
Intern Med; 2021 Jan; 60(1):59-66. PubMed ID: 32830176
[TBL] [Abstract][Full Text] [Related]
4. Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study.
Sameshima S; Koketsu S; Okuyama T; Kubota Y; Ono Y; Noie T; Oya M
World J Surg Oncol; 2016 Jul; 14(1):192. PubMed ID: 27450459
[TBL] [Abstract][Full Text] [Related]
5. [A case of inferior vena cava thrombosis and acute pancreatitis in a patient with ulcerative colitis].
Shin DH; Lee KH; Kim CH; Kim KH; Park SH; Chang DK; Lee JK; Lee KT
Korean J Gastroenterol; 2010 Oct; 56(4):255-9. PubMed ID: 20962562
[TBL] [Abstract][Full Text] [Related]
6. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
Schreiber S; Hanauer SB; Sandborn WJ; Barrett K
J Crohns Colitis; 2020 Sep; 14(9):1274-1281. PubMed ID: 32179906
[TBL] [Abstract][Full Text] [Related]
7. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
[TBL] [Abstract][Full Text] [Related]
9. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report.
Rieker L; Hofer J; Petzold G; Ellenrieder V; Amanzada A
BMC Gastroenterol; 2022 Jan; 22(1):22. PubMed ID: 35033015
[TBL] [Abstract][Full Text] [Related]
10. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report.
Khanna RK; Hage R; Hage A; Polin V; Sené T; Vignal-Clermont C
Medicine (Baltimore); 2018 Dec; 97(49):e13365. PubMed ID: 30544405
[TBL] [Abstract][Full Text] [Related]
12. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
15. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
16. Remission of ulcerative colitis flare-up induced by nivolumab.
Iwamoto M; Kato K; Moriyama M; Yamaguchi K; Takahashi S
Int J Colorectal Dis; 2020 Sep; 35(9):1791-1795. PubMed ID: 32458394
[TBL] [Abstract][Full Text] [Related]
17. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
18. Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
Buurman DJ; De Monchy JG; Schellekens RC; van der Waaij LA; Kleibeuker JH; Dijkstra G
Scand J Gastroenterol; 2015 Apr; 50(4):399-405. PubMed ID: 25633468
[TBL] [Abstract][Full Text] [Related]
19. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
20. Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case.
Dorofeyev AE; Rassokhina OA; Dorofeyeva AA
Dig Dis; 2017; 35(1-2):45-49. PubMed ID: 28147350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
